Brussels, 16 April 2026 - Mr. Tetsuya Tanaka, Managing Director & CEO of JBA, participated in the 27th Annual Meeting of the Japan-EU Business Round Table (BRT).
At this BRT Annual Meeting, government officials and business leaders from both Japan and the EU convened for in-depth discussions on global trade, economic security, and industrial competitiveness. Given the current global uncertainties, both parties highlighted the importance of Japan and the EU aligning further in enhancing supply chain resilience and driving international standardization as strategic partners sharing fundamental values.
During the session for Working Party 2 (WP2), covering Life Sciences, Healthcare, and the Bioeconomy, Mr. Osamu Nagayama, the Honorary Chairperson of Chugai Pharmaceutical Co., Ltd. (and Honorary President of JBA), delivered a presentation as the representative of WP2. He strongly advocated for the promotion of a sustainable future through life sciences and the bioeconomy, as well as the enhancement of innovation in areas such as healthcare and biomanufacturing.
In response, Mr. Tetsuya Tanaka emphasized that "it is essential to foster a strong ecosystem for drug discovery innovation," and called for Japan and the EU to take the lead in promoting the bioeconomy.
The Working Party Reports and Joint Recommendations adopted at the meeting were submitted to the Japanese and the EU authorities. JBA remains committed to realizing these recommendations and will continue to contribute to the further development of the Japanese bioindustry.
